Therapy of metastatic castration-resistant prostate cancer with Talazoparib + Enzalutamide under real world conditions in Germany – an observational medical chart review study (PROTEGE study) First published 17/12/2025 Last updated 09/01/2026 EU PAS number:EUPAS1000000593 Study Ongoing